Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Authors:
- William StohlWSWilliam Stohl
- Joan T. MerrillJMJoan T. Merrill
- James D. McKayJMJames D. McKay
- Jeffrey R. LisseJLJeffrey R. Lisse
- Z. John ZhongZZZ. John Zhong
- William W. FreimuthWFWilliam W. Freimuth
- Mark C. GenoveseMGMark C. Genovese
- 1 April 2013
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (5) , 579-589
Abstract
Objective. To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods. Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response. Results. Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups. Conclusion. In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]Keywords
This publication has 39 references indexed in Scilit:
- Rheumatoid arthritisThe Lancet, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAAnnals of the Rheumatic Diseases, 2010
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onsetAnnals of the Rheumatic Diseases, 2006
- B cells in rheumatoid synovitisArthritis Research & Therapy, 2005
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003
- Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damageAnnals of the Rheumatic Diseases, 2003
- Contribution of patient related differences to multidrug resistance in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohortArthritis & Rheumatism, 2002